Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael O. Clarke"'
Autor:
Timothy P. Sheahan, Amy C. Sims, Sarah R. Leist, Alexandra Schäfer, John Won, Ariane J. Brown, Stephanie A. Montgomery, Alison Hogg, Darius Babusis, Michael O. Clarke, Jamie E. Spahn, Laura Bauer, Scott Sellers, Danielle Porter, Joy Y. Feng, Tomas Cihlar, Robert Jordan, Mark R. Denison, Ralph S. Baric
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Remdesivir (RDV) is a broad-spectrum antiviral drug with activity against MERS coronavirus, but in vivo efficacy has not been evaluated. Here, the authors show that RDV has superior anti-MERS activity in vitro and in vivo compared to combination ther
Externí odkaz:
https://doaj.org/article/f17353d0fecb47bb853401bd79786ace
Autor:
Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, Everett Clinton Smith, James Brett Case, Joy Y. Feng, Robert Jordan, Adrian S. Ray, Tomas Cihlar, Dustin Siegel, Richard L. Mackman, Michael O. Clarke, Ralph S. Baric, Mark R. Denison
Publikováno v:
mBio, Vol 9, Iss 2 (2018)
ABSTRACT Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity. We recently
Externí odkaz:
https://doaj.org/article/1b011f9fd4ae445884489fb5ef613ee9
Autor:
Stuart T. Nichol, Brett P. Eaton, Nate Larson, Ginger Donnelly, Mike Flint, Robert Jordan, Douglas L. Mayers, Michel Perron, Yeojin Park, Dustin Siegel, Lydia Wolfe, Veronica Soloveva, Edward Doerffler, William A. Lee, Donald K. Nichols, Dima N. Gharaibeh, Elizabeth C. Grimes, Laura Gomba, Darius Babusis, Travis K. Warren, Kwon Soo Chun, Tomas Cihlar, Queenie Wang, Adrian S. Ray, Kirsten M. Stray, Bruce Ross, Elyse R. Nagle, Kelly S. Stuthman, Lisa S. Welch, Rachel Fearns, Jonathan E. Nuss, Willard Lew, Jeffrey R. Kugelman, Molly R. Braun, Roy Bannister, Richard L. Mackman, Pamela Wong, Christina F. Spiropoulou, Joy Y. Feng, Hui Hon Chung, Ona Barauskas, Sean Neville, Jay Wells, Robert G. Strickley, Catherine L. Wilhelmsen, S. Swaminathan, Iva Trancheva, Nicole L. Garza, Cary Retterer, Michael K. Lo, Sean A. Van Tongeren, Gustavo Palacios, Laura K. McMullan, Amy C. Shurtleff, Lijun Zhang, Michael O. Clarke, Yili Xu, Sina Bavari, Tara Kenny, Ernest Carra, Rouzbeh Zamani, Shan Shan Chen
Publikováno v:
Nature
The most recent Ebola virus outbreak in West Africa, which was unprecedented in the number of cases and fatalities, geographic distribution, and number of nations affected, highlights the need for safe, effective, and readily available antiviral agen
Autor:
Lisa E. Gralinski, Robert Jordan, James Brett Case, Christopher A. Palmiotti, Richard L. Mackman, Amy C. Sims, Jamie E. Spahn, Iva Trantcheva, Roy Bannister, Timothy P. Sheahan, Joy Y. Feng, Darius Babusis, Ralph S. Baric, Vineet D. Menachery, Dustin Siegel, Michael O. Clarke, Yeojin Park, Adrian S. Ray, Tomas Cihlar, Mark R. Denison, Krzysztof Pyrc, Sarah R. Leist, Rachel L. Graham
Publikováno v:
Science Translational Medicine
Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a procli
Autor:
Punya Shrivastava-Ranjan, Michael O. Clarke, Michel Perron, Richard L. Mackman, Michael K. Lo, Tomas Cihlar, Stuart T. Nichol, Laura K. McMullan, Hui Hon Chung, Christina F. Spiropoulou, Robert Jordan, Dustin Siegel, Mike Flint, Aaron Arvey, Jawahar Sudhamsu, Anne L. Hotard, Adrian S. Ray
Publikováno v:
Scientific Reports
GS-5734 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a non-human primate model of Ebola virus infection. It has been administered under compassionate use to two Ebola patients, both of whom survived
Autor:
Travis J. Williams, Theodore C. Jessop, Joshua C. Horan, Gabriel G. Gamber, Paul A. Wender, Cindy Kan, Kanaka Pattabiraman, Stacey E. Brenner, Michael O. Clarke, Jeremy L. Baryza
Publikováno v:
Pure and Applied Chemistry. 75:143-155
Studies in our laboratory focus on problems in chemistry (new reactions and syn- thesis), biology (novel modes of action), and medicine (new therapeutic leads and drug deliv- ery systems). These interconnected and often synergistic activities are ins
Autor:
Martijn Fenaux, D. Sauer, Edward Doerffler, Thomas Butler, Willard Lew, Lijun Zhang, Sammy Metobo, Anne Carey, Cynthia Kim, Adrian S. Ray, S. Rossi, Aktoudianakis, Michael O. Clarke, J. Xu, Ting Wang, Darius Babusis, Weidong Zhong, A. Cho, John G. McHutchison, Daniel Byun, Hong Ye, P. German, Jason K. Perry, Joy Y. Feng, R. Lee
Publikováno v:
Journal of medicinal chemistry. 57(5)
Hepatitis C virus (HCV) infection presents an unmet medical need requiring more effective treatment options. Nucleoside inhibitors (NI) of HCV polymerase (NS5B) have demonstrated pan-genotypic activity and durable antiviral response in the clinic, an
Autor:
Martijn Fenaux, Stacey Eng, Stephanie A. Leavitt, Yu-Jen Lee, Eric M. Mabery, Yang Tian, Daniel Byun, Eda Canales, Michael O. Clarke, Edward Doerffler, Scott E. Lazerwith, Willard Lew, Qi Liu, Michael Mertzman, Philip Morganelli, Lianhong Xu, Hong Ye, Jennifer Zhang, Mike Matles, Bernard P. Murray, Judy Mwangi, Jingyu Zhang, Ahmad Hashash, Steve H. Krawczyk, Alison M. Bidgood, Todd C. Appleby, William J. Watkins
GS-9669 is a highly optimized thumb site II nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, with a binding affinity of 1.35 nM for the genotype (GT) 1b protein. It is a selective inhibitor of HCV RNA replication, with a mean 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d66793ecfe602fea0d21fe4a59c1e4
https://europepmc.org/articles/PMC3553741/
https://europepmc.org/articles/PMC3553741/
Autor:
Stacey E. Brenner, Jeremy L. Baryza, Joshua C. Horan, Madeleine L. Craske, Paul A. Wender, Tobias Meyer, Michael O. Clarke
Publikováno v:
Current drug discovery technologies. 1(1)
Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile. Its natural and synthetic availability is severely limited. Function oriented synthesis provides a means to address this supply problem through the design of
Publikováno v:
Organic letters. 7(10)
The syntheses of three newly designed bryostatin analogues are reported. These simplified analogues, which lack the A-ring present in the natural product but possess differing groups at C9, were obtained using a divergent approach from a common inter